GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Foghorn Therapeutics Inc (NAS:FHTX) » Definitions » Shares Outstanding (Basic Average)

FHTX (Foghorn Therapeutics) Shares Outstanding (Basic Average) : 62.85 Mil (As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is Foghorn Therapeutics Shares Outstanding (Basic Average)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Foghorn Therapeutics's average basic shares outstanding for the quarter that ended in Mar. 2025 was 62.85 Mil.


Foghorn Therapeutics Shares Outstanding (Basic Average) Historical Data

The historical data trend for Foghorn Therapeutics's Shares Outstanding (Basic Average) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Foghorn Therapeutics Shares Outstanding (Basic Average) Chart

Foghorn Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shares Outstanding (Basic Average)
Get a 7-Day Free Trial 11.05 37.17 41.59 41.97 54.90

Foghorn Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Shares Outstanding (Basic Average) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 42.43 51.58 62.60 62.87 62.85

Foghorn Therapeutics Shares Outstanding (Basic Average) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Foghorn Therapeutics  (NAS:FHTX) Shares Outstanding (Basic Average) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.


Be Aware

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Foghorn Therapeutics Shares Outstanding (Basic Average) Related Terms

Thank you for viewing the detailed overview of Foghorn Therapeutics's Shares Outstanding (Basic Average) provided by GuruFocus.com. Please click on the following links to see related term pages.


Foghorn Therapeutics Business Description

Industry
Traded in Other Exchanges
N/A
Address
500 Technology Square, Suite 700, Cambridge, MA, USA, 02139
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
Executives
Carlos Costa officer: Chief People Officer C/O FOGHORN THERAPEUTICS INC., 500 TECHNOLOGY SQUARE, SUITE 700, CAMBRIDGE MA 02139
Steven F. Bellon officer: See Remarks 500 TECHNOLOGY SQUARE, SUITE 700, CAMBRIDGE MA 02139
Fanny Cavalie officer: Chief Strategy/Bus Ops Officer C/O FOGHORN THERAPEUTICS INC., 500 TECHNOLOGY SQUARE, SUITE 700, CAMBRIDGE MA 02139
Alfonso Quintas Cardama officer: Chief Medical Officer C/O TCR2 THERAPEUTICS INC., 100 BINNEY STREET, CAMBRIDGE MA 02142
Samuel Agresta officer: Chief Medical Officer 784 MEMORIAL DR., CAMBRIDGE MA 02139
Lynch Thomas J. Jr. director 800 HOWARD AVENUE, YALE PHYSICIANS BUILDING, 2ND FLOOR, NEW HAVEN CT 06519
B Lynne Parshall director 2855 GAZELLE COURT, CARLSBAD CA 92010
Ian F Smith director C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Michael Lacascia officer: Chief Legal Officer 500 TECHNOLOGY SQUARE, SUITE 700, CAMBRIDGE MA 02139
Carl Decicco officer: Chief Scientific Officer 100 BINNEY STREET, SUITE 610, CAMBRIDGE MA 02142
Flagship Ventures Opportunities Fund I General Partner Llc 10 percent owner 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Abu Dhabi Investment Authority 10 percent owner 211 CORNICHE STREET, PO BOX 3600, ABU DHABI C0 0000
Platinum International Investment Holding Rsc Ltd 10 percent owner 26TH FLOOR, AL KHATEM TOWER, ADGM SQUARE, PO BOX 25642, AL MARYAH ISLAND, ABU DHABI C0 NA
Adam Koppel director C/O BROOKSIDE CAPITAL, LLC, JOHN HANCOCK TOWER, 200 CLARENDON ST, BOSTON MA 02116
Jose Baselga director 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139